新型隐球菌临床分离株和环境分离株对五种抗真菌药物的体外敏感性
In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
作者信息
Franzot S P, Hamdan J S
机构信息
Department of Microbiology, Federal University of Minas Gerais, Brazil.
出版信息
Antimicrob Agents Chemother. 1996 Mar;40(3):822-4. doi: 10.1128/AAC.40.3.822.
Abstract
A total of 53 Cryptococcus neoformans strains, including clinical and environmental Brazilian isolates, were tested for their susceptibilities to amphotericin B, 5-flucytosine, ketoconazole, fluconazole, and itraconazole. The tests were performed according to the National Committee of Clinical Laboratory Standards recommendations (document M27-P). In general, there was a remarkable homogeneity of results for all strains, and comparable MICs were found for environmental and clinical isolates. This paper represents the first contribution in which susceptibility data for Brazilian C. neoformans isolates are provided.
摘要
共对53株新型隐球菌菌株进行了测试，这些菌株包括巴西临床分离株和环境分离株，检测它们对两性霉素B、5-氟胞嘧啶、酮康唑、氟康唑和伊曲康唑的敏感性。测试按照美国国家临床实验室标准委员会的建议（文件M27-P）进行。总体而言，所有菌株的结果具有显著的同质性，环境分离株和临床分离株的最低抑菌浓度（MIC）相当。本文首次提供了巴西新型隐球菌分离株的药敏数据。
相似文献
1
In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
Antimicrob Agents Chemother. 1996 Mar;40(3):822-4. doi: 10.1128/AAC.40.3.822.
2
Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
Braz J Infect Dis. 2012 Mar-Apr;16(2):175-9. doi: 10.1016/s1413-8670(12)70301-x.
3
In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil.
Rev Inst Med Trop Sao Paulo. 2001 Sep-Oct;43(5):267-70. doi: 10.1590/s0036-46652001000500006.
4
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients.
Diagn Microbiol Infect Dis. 1995 Nov;23(3):99-103. doi: 10.1016/0732-8893(95)00169-7.
5
Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Rev Inst Med Trop Sao Paulo. 2005 Sep-Oct;47(5):253-6. doi: 10.1590/s0036-46652005000500003. Epub 2005 Nov 16.
6
Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela.
J Clin Microbiol. 2001 Jun;39(6):2348-50. doi: 10.1128/JCM.39.6.2348-2350.2001.
7
In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Mycoses. 2006 Jul;49(4):324-30. doi: 10.1111/j.1439-0507.2006.01242.x.
8
[Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Rev Soc Bras Med Trop. 2008 Mar-Apr;41(2):158-62. doi: 10.1590/s0037-86822008000200005.
9
In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
J Mycol Med. 2012 Sep;22(3):243-8. doi: 10.1016/j.mycmed.2012.06.002. Epub 2012 Aug 10.
10
Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Med Mycol. 2019 Oct 1;57(7):864-873. doi: 10.1093/mmy/myy150.
引用本文的文献
1
Advanced approach for antifungal susceptibility and characterization of resistance properties in clinical and environmental isolates of species complex.
Infect Med (Beijing). 2022 Aug 29;1(3):147-153. doi: 10.1016/j.imj.2022.08.006. eCollection 2022 Sep.
2
Species Complexes from Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B.
Infect Drug Resist. 2020 Feb 26;13:673-681. doi: 10.2147/IDR.S235473. eCollection 2020.
3
Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Braz J Microbiol. 2015 Oct-Dec;46(4):1125-33. doi: 10.1590/S1517-838246420140564. Epub 2015 Oct 27.
4
Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.
BMC Infect Dis. 2012 Dec 20;12:361. doi: 10.1186/1471-2334-12-361.
5
Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans.
Mycopathologia. 2012 Jun;173(5-6):427-33. doi: 10.1007/s11046-012-9528-9. Epub 2012 Feb 22.
6
Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.
Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1525-32. doi: 10.1007/s10096-010-1034-8. Epub 2010 Aug 28.
7
DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples.
Mycopathologia. 2005 Aug;160(1):9-14. doi: 10.1007/s11046-005-6332-9.
8
The isolation, characterization and antifungal susceptibilities of Cryptococcus neoformans from bird excreta in Klang Valley, Malaysia.
Mycopathologia. 2005 Jun;159(4):509-13. doi: 10.1007/s11046-005-3091-6.
9
Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas.
Mycopathologia. 2005 Jan;159(1):7-11. doi: 10.1007/s11046-004-9618-4.
10
In vitro antifungal susceptibility of Cryptococcus gattii.
J Clin Microbiol. 2004 Oct;42(10):4815-7. doi: 10.1128/JCM.42.10.4815-4817.2004.
本文引用的文献
1
Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media.
J Clin Microbiol. 1993 May;31(5):1370-2. doi: 10.1128/jcm.31.5.1370-1372.1993.
2
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.
Antimicrob Agents Chemother. 1993 Jan;37(1):39-45. doi: 10.1128/AAC.37.1.39.
3
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.
Antimicrob Agents Chemother. 1993 Jun;37(6):1383-6. doi: 10.1128/AAC.37.6.1383.
4
Antifungal susceptibility testing.
Clin Microbiol Rev. 1993 Oct;6(4):367-81. doi: 10.1128/CMR.6.4.367.
5
Susceptibility testing of fungi: current status of the standardization process.
Antimicrob Agents Chemother. 1993 Dec;37(12):2517-21. doi: 10.1128/AAC.37.12.2517.
6
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City.
J Clin Microbiol. 1994 May;32(5):1188-92. doi: 10.1128/jcm.32.5.1188-1192.1994.
7
Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B.
Antimicrob Agents Chemother. 1994 Nov;38(11):2648-50. doi: 10.1128/AAC.38.11.2648.
8
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.
J Clin Microbiol. 1994 Oct;32(10):2494-500. doi: 10.1128/jcm.32.10.2494-2500.1994.
9
Antifungal drug susceptibility testing.
J Med Vet Mycol. 1994;32 Suppl 1:267-76. doi: 10.1080/02681219480000891.
10
Resistance of Candida species to fluconazole.
Antimicrob Agents Chemother. 1995 Jan;39(1):1-8. doi: 10.1128/AAC.39.1.1.
Zotero 插件